Spironolactone for hirsutism in polycystic ovary syndrome

Annals of Pharmacotherapy

Volumn 39, Issue 9, 2005, Pages 1517-1521

  Christy, Natalie A ^a,b   Franks, Andrea S ^b   Cross, L Brian ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Hirsutism; Polycystic ovary syndrome; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIANDROGEN; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; FINASTERIDE; FLUTAMIDE; METFORMIN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE;

CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; EMBASE; HIRSUTISM; HUMAN; MEDLINE; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW;

ALDOSTERONE ANTAGONISTS; FEMALE; HIRSUTISM; HUMANS; POLYCYSTIC OVARY SYNDROME; SPIRONOLACTONE;

EID: 23944505473     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G025     Document Type: Review

References (20)

1. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek isle of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;85:2434-8.
3. Stein IL, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-9.
4. Rebar R, Judd HL, Yen SS, Rakoff J, Vanderberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 1976;57:1320-9.
5. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
6. National Institutes of Health Consensus Meeting on PCOS. In: Dunaif A, ed. Current issues in endocrinology and metabolism. Boston: Blackwell Scientific, 1992:377-84.
7. Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Am Rev Med 2001;52:401-19.
8. Birdsall MA, Farquhar CM, White HD. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32-5.
9. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61:403-7.
10. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
11. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001;16:556-60.
12. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599-604.
13. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003;67:25-32.
14. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, et al. Drosperinone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817-23.
15. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89-94.
16. Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol 2000;52:587-94.
17. Wong IL, Morris RS, Chang L, Spahn M, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995;80:233-8.
18. Milewicz A, Silber D, Kirschner M. Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol 1983;61:429-32.
19. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1140-8.
20. Ganie MA, Khurana ML, Eunice M, Gulati M, Dwivedi N, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004;89:2756-62.